portfolio strategy

Key Disruptors in The Multiple Myeloma Landscape: 2020 and Beyond

Accelerated innovation in drug design and development is providing diverse treatment options for cancer patients, including hematological malignancies, like multiple myeloma. However, innovation has complicated physicians’ therapy selection and decision making, including how best to sequence treatment across lines of therapy. Thereby contributing to an unmet need for indications like multiple myeloma, that are typically […]

Four NMEs Hope to Keep Up Momentum in the U.S. Migraine Market

For these new entrants, differentiation is evident but access is critical – and each faces market headwinds. 2018 marked a turning point in the U.S. migraine market with the launch of three anti-CGRP monoclonal antibodies (MAbs): Novartis/Amgen’s Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality. Not only did these products become the first migraine-specific drugs approved […]

First-in-class Tazverik launched for rare sarcoma, wider use will drive market value

Epizyme’s first-in-class EZH2 (enhancer of zeste homolog 2) inhibitor Tazverik (tazemetostat) has become the first therapy to be made available in the U.S. for the treatment of epithelioid sarcoma (ES), a rare soft tissue tumor with a significant unmet need.1,2,3 The drug was granted accelerated approval in January 2020 for the treatment of patients aged […]

ASH 2019: How Can CAR T-cell Developers Ensure Differentiation in NHL?

Commercial availability of two anti-CD19 CAR T-cell therapies (Kite/Gilead’s Yescarta and Novartis’ Kymriah) has revolutionized treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). To date, the efficacy of these novel therapies has been impressive, but severe side effects, logistical hurdles, and reimbursement delays have hindered delivery of these personalized treatments […]

Digital Therapeutics Target Mental Health, Substance Use Disorders

As advancements in technology-assisted treatments evolve, digital therapeutics are emerging as a vehicle for mental health and addiction treatment. Digital therapeutics have the potential to close gaps in care for patients, reduce demands on providers’ time, and enhance the effectiveness of pharmaceuticals, offering promise for stakeholders across the spectrum of healthcare delivery.   What are […]

Results from PARP Inhibitor Trials Point to Drastic Changes for Ovarian Cancer Management

What ESMO 2019 announcements mean for the future of the ovarian cancer market and patient care PARP inhibitors have shown extremely encouraging data that could help pave the way for an entirely new treatment algorithm in ovarian cancer. These agents have given patients the opportunity for more effective treatments in the frontline and recurrent settings. […]

Malignant Melanoma – Is Cure a Possibility?

5-year survival data from CheckMate-067 trial released at ESMO 2019, highlighting the efficacy of immunotherapy in the treatment of malignant melanoma, regardless of BRAF status In the last decade, immunotherapy has revolutionised the treatment of malignant melanoma. Before 2011, no effective treatment was available for this chemotherapy-resistant cancer, and patients with metastatic disease (stage IV) […]

Tracing the Treatment Journey Using Real-World Data

Like the pharmaceutical industry as a whole, the market research and business intelligence functions within have experienced a tremendous transformation over the years—and continue to change. With increasing pressure on resources, heightened competition, and growing complexity of the market landscape, market researchers and the teams the support often need to do more with less, deliver […]

Biktarvy, the booming blockbuster, drives HIV market

From gene therapies and vaccines, to combination therapies and antibodies, treatments in the Cortellis Drugs to Watch 2018 report were varied both in action and target. The  Cortellis team featured 12 potential blockbusters last year which had forecasted sales of more than $1 billion by 2022.  One treatment stood out, due to its achievement of […]

ASCO 2019: The future of Keytruda plus chemo combination therapy

Checkpoint inhibitor combination strategies remains a focus of development, but chemo combos are not a slam dunk for every indication. As the 40,000 attendees of this year’s ASCO conference relinquish their hold of the windy city, oncology experts worldwide begin contemplating the wealth of new or expanded data which was presented, and how it might […]